Orion receives approval from Chinese NMPA for darolutamide

In the trial, darolutamide and ADT along with docetaxel, demonstrated significant reduction in death risk by 32.5% against ADT with docetaxel, in patients with mHSPC. Credit: Nephron / commons.wikimedia.org.